The development of monocyclic pyrazolone based cytokine synthesis inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 9, 2005, Pages 2285-2289

  Golebiowski, Adam ^a   Townes, Jennifer A ^a   Laufersweiler, Matthew J ^a   Brugel, Todd A ^a   Clark, Michael P ^a   Clark, Cynthia M ^a   Djung, Jane F ^a   Laughlin, Steven K ^a   Sabat, Mark P ^a   Bookland, Roger G ^a   VanRens, John C ^a   De, Biswanath ^a   Hsieh, Lily C ^a   Janusz, Michael J ^a   Walter, Richard L ^a   Webster, Mark E ^a   Mekel, Marlene J ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Cytokine synthesis inhibitors; p38 kinase

Indexed keywords

IODOACETIC ACID; LIPOPOLYSACCHARIDE; PYRAZOLONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SYNTHESIS; GENE MUTATION; MALE; NONHUMAN; OSTEOARTHRITIS; RAT; X RAY CRYSTALLOGRAPHY;

EID: 20244384146     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.03.007     Document Type: Article

References (17)

1. For a recent review, see: J.L. Adams, A.M. Badger, S. Kumar, and J.C. Lee p38 MAP Kinase: Molecular Target for the Inhibition of Pro-inflammatory Cytokines F.D. King A.W. Oxford Progress in Medicinal Chemistry 38 2001 Elsevier Amsterdam 1 60
2. A.M. Badger, J.N. Bradbeer, B. Votta, J.C. Lee, J.L. Adams, and D.E. Griswold J. Pharmacol. Exp. Ther. 279 1996 1453
3. J.C. Boehm, and J.L. Adams Expert Opin. Ther. Pat. 10 2000 25
4. P.F. Jackson, and J.L. Bullington Curr. Top. Med. Chem. 2 2002 1011
5. J.S. Tullis, J.C. VanRens, M.G. Natchus, M.P. Clark, B. De, L.C. Hsieh, and M.J. Janusz Bioorg. Med. Chem. Lett. 13 2003 1665
6. S.E. deLaszlo, D. Visco, L. Agarwal, L. Chang, J. Chin, G. Croft, A. Forsyth, D. Fletcher, B. Frantz, C. Hacker, W. Hanlon, C. Harper, M. Kostura, B. Li, S. Luell, M. MacCoss, N. Mantlo, E.A. O'Neill, C. Orevillo, M. Pang, J. Parson, A. Rolando, Y. Sahly, K. Sidler, W.R. Widmer, and S.J. O'Keefe Bioorg. Med. Chem. Lett. 8 1998 2689
7. M.P. Clark, S.K. Laughlin, M.J. Laufersweiler, R.B. Bookland, T.A. Brugel, A. Golebiowski, M.P. Sabat, J.A. Townes, J.C. VanRens, J.F. Djung, M.G. Natchus, B. De, L.C. Hsieh, S.C. Xu, S.A. Heitmeyer, K.K. Brown, K. Juergens, R.L. Walter, M.J. Mekel, Y.O. Taiwo, and M.J. Janusz J. Med. Chem. 47 2004 2724
8. M.J. Laufersweiler, T.A. Brugel, M.P. Clark, A. Golebiowski, R.G. Bookland, S.K. Laughlin, M.P. Sabat, J.A. Townes, J.C. VanRens, B. De, L.C. Hsieh, S.A. Heitmeyer, K. Juergens, K.K. Brown, M.J. Mekel, R.L. Walter, and M.J. Janusz Bioorg. Med. Chem. Lett. 14 2004 4267
9. Laughlin, S. K.; Clark, M. P.; Djung, J. F.; Golebiowski, A.; Brugel, T. A.; Sabat, M. P.; Bookland, R. G.; Laufersweiler, M. J.; VanRens, J. C.; Townes, J. A.; De, B.; Hsieh, L. C.; Xu, S. C.; Walter, R. L.; Mekel, M. J.; Janusz, M. J. Bioorg. Med. Chem. Lett., submitted for publication
10. A.B. Smith III Synthesis 1981 567
11. 15 (Promega Co., Madison, WI). Standard deviation for THP-1 cellular assays were typically ±30% of the mean or less
12. Selective acetylation of methyl hydrazine was previously reported: P.P. Norton, and S. Shyam J. Heterocycl. Chem. 14 1977 1447
13. The mutated p38α herein described is an inactivated, double mutant (S180A, Y182F) of murine p38α. For more details see Ref. 7. The crystal structure of compound 15d bound to mutated p38α-kinase has been deposited in the Protein Data Bank with RCSB/PDB information is as follows: PDB Code: 1YWR; RCSB code: RCSB032009
14. K.M. Mohler, P.R. Sleath, J.N. Fitzner, D.P. Cerretti, M. Alderson, S.S. Kerwar, D.S. Torrance, C. Otten-Evans, T. Greenstreet, K. Weerawarna, S.R. Kronhelm, M. Petersen, M. Gerhart, C.J. Kozlosky, C.J. March, and R.A. Black Nature 370 1994 218
15. J.A. Barltrop, T.C. Owen, A.H. Cory, and J.G. Cory Bioorg. Med. Chem. Lett. 1 1991 611
16. Sprague-Dawley male rats (200-225 g) from Harlan (Oregon, WI) under anesthesia were injected in the patellar ligament region of the left leg (flexed 90°at the knee) with 20 μL of a 10 mg/mL concentration of monosodium iodoacetate (IA) (Aldrich Chemical, Milwaukee, WI). Animals (groups of 15) were dosed for 7 days BID (∼every 12 h) with the potential inhibitor (25 mg/kg) or vehicle (2.5 mL/kg). Animals were sacrificed on day 22 and the left joint was disarticulated and fixed in 10% formalin for 24-48 h prior to capturing the image. An image of the tibial cartilage surface was captured using an Optimas (Optimas, Media Cybernetics LP, Silver Springs, MA) image analysis system. Three independent observers assessed the damage in a blinded manner using a scale of 0-4 of increasing severity (0 = normal; 4 = maximum severity)
17. M.J. Janusz, E.B. Hookfin, S.A. Heitmeyer, J.F. Woessner, A.J. Freemont, J.A. Hoyland, K.K. Brown, L.C. Hsieh, N.G. Almstead, B. De, M.G. Natchus, S. Pikul, and Y.O. Taiwo Osteoarthr. Cartilage 9 2001 751